Novel 5α-Reductase Inhibitors: Synthesis, Structure−Activity Studies, and Pharmacokinetic Profile of Phenoxybenzoylphenyl Acetic Acids
Citations Over Time
Abstract
Novel substituted benzoyl benzoic acids and phenylacetic acids 1-14 have been synthesized and evaluated for inhibition of rat and human steroid 5alpha-reductase isozymes 1 and 2. The compounds turned out to be potent and selective human type 2 enzyme inhibitors, exhibiting IC(50) values in the nanomolar range. The phenylacetic acid derivatives were more potent than the analogous benzoic acids. Bromination in the 4-position of the phenoxy moiety led to the strongest inhibitor in this class (12; IC(50) = 5 nM), which was equipotent to finasteride. Since oral absorption is essential for a potential drug, 12 was further examined. In the parallel artificial membrane permeation assay (PAMPA) it turned out to be a good permeator, whereas it was a medium permeator in Caco2 cells. After oral administration (40 mg/kg) to rats a high bioavailability and a biological half-life of 5.5 h were observed, making it a promising candidate for clinical evaluation.
Related Papers
- → Evaluation of pharmacokinetic properties of vitacoxib in fasted and fed horses(2018)8 cited
- → The increasing doses of methotrexate pharmacokinetics after intravenous administration in rats - model selection(2019)3 cited
- → Pharmacokinetics of 2',3'-dideoxyinosine in monkeys(1991)20 cited
- Pharmacokinetics of monoclonal antibody HAb 18 and its F(ab^)_(2) and fab fragments in mice(1996)
- Pharmacokinetics and tissue distribution of Chuanhuning emuslion in rats(2014)